Skip to content

Efficacy and safety of Absorbable Peripheral Nerve Repair Materials Compared with Acellular Matrix Peripheral Nerve Repair Membrane in the Repair of Upper Limb Peripheral Nerve Injury:A single-center randomized controlled clinical trial

Efficacy and safety of Absorbable Peripheral Nerve Repair Materials Compared with Acellular Matrix Peripheral Nerve Repair Membrane in the Repair of Upper Limb Peripheral Nerve Injury:A single-center randomized controlled clinical trial

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096489
Enrollment
Unknown
Registered
2025-01-24
Start date
2025-01-25
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper Limb Peripheral Nerve Injury

Interventions

Experimental group:Use Absorbable Peripheral Nerve Repair Materials
Control Group:Use Acellular Matrix Peripheral Nerve Repair Membrane

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1)age >=18 years and < 70 years; 2)Upper limb traumatic nerve injury (with an injury gap that can be end-to-end anastomosed) or cubital tunnel syndrome; 3)Signed informed consent form; 4)The injured site is operable; 5)There is an uninjured contralateral upper limb or adjacent finger, suitable as a reference for baseline function assessment; 6)able to comply with all aspects of the treatment and evaluation plan within a 12-month period; 7)no pregnant or breastfeeding; 8)No autoimmune diseases or other serious physical illnesses that may affect the study; 9)No mental disorders; 10)No history of neuropathy, diabetic neuropathy, or other known neuropathies; 11)No history of chronic ischemic disease or vasculitis in the upper limbs.

Exclusion criteria

Exclusion criteria: 1)Participation in other clinical studies within the past 3 months; 2)unable to do surgery; 3)Allergy to the repair materials; 4)Extensive soft tissue injury that affects the assessment of recovery; 5)Known medications that will be used during the study period and are known to affect nerve regeneration or cause peripheral neuropathy; 6)Subjects who are currently receiving or are expected to receive chemotherapy, radiation therapy, or other treatments known to affect the growth of the nervous and/or vascular system; 7)Multiple segment injuries of a single nerve; 8)Injuries distal to the distal interphalangeal joint; 9)Side-to-end nerve repair; 10)Injuries where vascular damage leads to insufficient perfusion after nerve repair; 11)Other forms of interfering injuries at the nerve ends, such as crush or traction injuries.

Design outcomes

Primary

MeasureTime frame
Meaningful Sensory Recovery Rate;

Secondary

MeasureTime frame
The British Medical Research Council Sensory Function Scale;Visual Analogue Scale;Semmes-Weinstein Monofilament;superficial sensation;Static Two-Point Discrimination / Dynamic Two-Point Discrimination;The British Medical Research Council Motor Function Scale;Grip Strength;Finger Joint Range of Motion;Pinch Force;Upper Extremity Function Assessment;

Countries

China

Contacts

Public ContactLi Wencui

Shenzhen Second People's Hospital

13923750767@163.com+86 139 2375 0767

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026